Literature DB >> 32254230

A fullerene-rhodamine B photosensitizer with pH-activated visible-light absorbance/fluorescence/photodynamic therapy.

Qianyun Tang1, Wanyue Xiao, Jiewei Li, Dapeng Chen, Yewei Zhang, Jinjun Shao, Xiaochen Dong.   

Abstract

The development of smart photosensitizers with tumor microenvironment-activable fluorescence turn-on and singlet oxygen generation plays an important role in tumor bioimaging and photodynamic therapy. Herein, a pH-activable heavy-atom-free photosensitizer (C60-RB) has been successfully synthesized through introducing a fullerene unit onto rhodamine B hydrazide. Under acidic conditions, C60-RB, having a spirolactam structure, can be activated to its ring-opened structure C60-RB-H and thus, visible-light absorbance enhancement, fluorescence turn-on and triplet excited state generation can be accomplished. In the presence of hydrion, the fullerene unit in C60-RB C60-RB-H acting as an intramolecular spin converter can cause good intersystem crossing, and the energy gap between S1 and T1 (ΔEST) is lowered to 0.017 eV. Through encapsulation with amphiphilic DSPE-mPEG2000, water-soluble nanoparticles (NPs) of C60-RB are obtained. In vitro experiments indicate that C60-RB NPs are capable of universal cellular uptake and lysosomal activation (pH 4.5-5.0), and they also exhibit excellent photodynamic therapeutic effect. The fluorescence turn-on and efficient singlet oxygen generation enabled by pH-activated C60-RB NPs testify their great potential applications for cancer diagnosis and treatment.

Entities:  

Year:  2018        PMID: 32254230     DOI: 10.1039/c8tb00372f

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  2 in total

1.  Photosensitized Oxidation of Intracellular Targets: Understanding the Mechanisms to Improve the Efficiency of Photodynamic Therapy.

Authors:  Thiago Teixeira Tasso; Maurício S Baptista
Journal:  Methods Mol Biol       Date:  2022

2.  Development of multifunctional nanocomposites for controlled drug delivery and hyperthermia.

Authors:  Vladimir Hovhannisyan; Katarina Siposova; Andrey Musatov; Shean-Jen Chen
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.